drugset / Trial / NCT03845166
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination with atezolizumab, and in combination with avelumab to subjects with advanced solid tumors.
Timeline
- Start
- 2019-03-20
- Primary completion
- 2026-08-31
- Completion
- 2027-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Avelumab | Monoclonal antibody | 800 mg | Intravenous |
| Subject | Zanzalintinib | Small molecule | — | Oral |